AR100291A2 - Composición catártica - Google Patents

Composición catártica

Info

Publication number
AR100291A2
AR100291A2 ARP130103006A ARP130103006A AR100291A2 AR 100291 A2 AR100291 A2 AR 100291A2 AR P130103006 A ARP130103006 A AR P130103006A AR P130103006 A ARP130103006 A AR P130103006A AR 100291 A2 AR100291 A2 AR 100291A2
Authority
AR
Argentina
Prior art keywords
formula
fatty acid
acid triglyceride
cathartic composition
bicyclic compound
Prior art date
Application number
ARP130103006A
Other languages
English (en)
Inventor
Ueno Ryuji
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24630250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR100291(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of AR100291A2 publication Critical patent/AR100291A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)

Abstract

Una suspensión o solución no acuosa que comprende un compuesto bicíclico representado por la fórmula (1), 13,14-dihidro-15-ceto-16,16-difluoro-prostaglandina E1, un compuesto el cual es un tautómero monocíclico de la fórmula (1), y un triglicérido de ácido graso, donde el triglicérido de ácido graso estabiliza la forma de dosificación en una relación de compuesto bicíclico a tautómero monocíclico de al menos 20:1.
ARP130103006A 2000-09-05 2013-08-26 Composición catártica AR100291A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/655,760 US6414016B1 (en) 2000-09-05 2000-09-05 Anti-constipation composition

Publications (1)

Publication Number Publication Date
AR100291A2 true AR100291A2 (es) 2016-09-28

Family

ID=24630250

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP010104216A AR030609A1 (es) 2000-09-05 2001-09-05 Composicion catartica
ARP130103006A AR100291A2 (es) 2000-09-05 2013-08-26 Composición catártica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP010104216A AR030609A1 (es) 2000-09-05 2001-09-05 Composicion catartica

Country Status (25)

Country Link
US (7) US6414016B1 (es)
EP (2) EP1315485B1 (es)
JP (3) JP2004508327A (es)
KR (2) KR100918223B1 (es)
CN (1) CN100335049C (es)
AR (2) AR030609A1 (es)
AT (1) ATE476975T1 (es)
AU (2) AU2001282615B2 (es)
BR (1) BRPI0114042B8 (es)
CA (1) CA2419741C (es)
CZ (1) CZ304740B6 (es)
DE (2) DE60142810D1 (es)
DK (2) DK1857105T3 (es)
ES (2) ES2296786T3 (es)
HU (1) HU229319B1 (es)
IL (2) IL154534A0 (es)
MX (1) MXPA03001959A (es)
NL (1) NL300757I1 (es)
NO (1) NO332701B1 (es)
NZ (1) NZ524401A (es)
PT (2) PT1857105E (es)
RU (1) RU2694361C3 (es)
TW (1) TWI305147B (es)
WO (1) WO2002020007A1 (es)
ZA (1) ZA200301673B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60039727D1 (de) * 1999-10-15 2008-09-11 Sucampo Ag Neue Zusammensetzung enthaltend eine bicyclische Verbindung und ein Glycerid
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
TWI331920B (en) 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
US7732487B2 (en) * 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
EP1562604B1 (en) * 2002-10-23 2012-01-04 Sucampo AG Prostaglandin compounds for the treatment of obesity
AU2003292556B2 (en) * 2002-12-27 2009-09-10 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort
US8337891B2 (en) 2003-07-03 2012-12-25 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI495471B (zh) * 2003-08-12 2015-08-11 R Tech Ueno Ltd 促進毛髮生長之組成物及方法
TWI387454B (zh) * 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
RU2392941C2 (ru) * 2004-09-02 2010-06-27 Сукампо Аг Производные простагландинов для лечения желудочно-кишечного нарушения
AU2006209072B2 (en) 2005-01-27 2011-02-24 Sucampo Ag Method and composition for treating central nervous system disorders
US8143316B2 (en) * 2005-03-04 2012-03-27 Sucampo Ag Method for treating peripheral vascular diseases
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN101171010B (zh) * 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
EP1871380B1 (en) * 2005-04-12 2011-10-19 Sucampo AG Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
CA2637275C (en) * 2006-01-24 2014-12-09 R-Tech Ueno, Ltd. Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
CN103804338A (zh) * 2006-02-07 2014-05-21 株式会社·R-技术上野 用于制备前列腺素衍生物的方法
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20090082442A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lubiprostone
CN101318948B (zh) * 2008-04-01 2011-04-27 上海天伟生物制药有限公司 鲁比前列酮晶体、其制备方法及用途
US8513441B2 (en) * 2008-08-29 2013-08-20 Alphora Research Inc. Prostaglandin synthesis and intermediates for use therein
WO2010049954A1 (en) * 2008-10-31 2010-05-06 Lipid Pharmaceuticals Ehf. Fatty acids for use as a medicament
KR20170091783A (ko) 2008-12-31 2017-08-09 알데릭스, 인코포레이티드 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP2429982A4 (en) 2009-01-22 2012-09-12 Apotex Pharmachem Inc METHOD FOR THE PRODUCTION OF LUBIPROSTON AND INTERMEDIATE PRODUCTS THEREOF
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
JP5797655B2 (ja) * 2009-09-18 2015-10-21 アドラー・コーポレーション 消化管障害のためのオピオイド受容体アンタゴニストの使用
CA2779736A1 (en) * 2009-11-03 2011-05-12 Bernard Charles Sherman Stable pharmaceutical formulations comprising lubiprostone
WO2011072383A1 (en) * 2009-12-18 2011-06-23 Apotex Pharmachem Inc. Processes for the purification of lubiprostone
EP2536705A4 (en) 2010-01-28 2013-08-07 Apotex Pharmachem Inc POLYMORPHIC FORMS OF LUBIPROSTON
AU2013304812B2 (en) 2012-08-21 2016-06-09 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
SMT201900386T1 (it) 2013-04-12 2019-09-09 Ardelyx Inc Composti nhe3-leganti e metodi per l'inibizione del trasporto di fosfato
US10736871B2 (en) 2015-04-01 2020-08-11 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
US20170020890A1 (en) * 2015-06-19 2017-01-26 Sucampo Ag Pharmaceutical composition comprising fatty acid derivative
JP6957610B2 (ja) 2016-10-06 2021-11-02 スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ 医薬品用途のための多層ビーズ
JP2020505333A (ja) 2017-01-09 2020-02-20 アルデリックス， インコーポレイテッド Ｎｈｅ媒介性アンチポートの阻害薬
AU2018205400C1 (en) 2017-01-09 2026-01-15 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
US10866140B2 (en) * 2017-04-20 2020-12-15 Shimadzu Corporation Spectrophotometer
US10422729B1 (en) 2019-03-08 2019-09-24 Biodesix, Inc. Blood sample separation devices and methods

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5720305B2 (es) 1973-02-28 1982-04-27
US4034003A (en) 1974-04-11 1977-07-05 Ono Pharmaceutical Co., Ltd. 15-Cycloalkyl-prostaglandins
JPS5350141A (en) 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
JPS5391110A (en) 1977-01-20 1978-08-10 Yamanouchi Pharmaceut Co Ltd Novel drug composition for rectal infusion
JPS6022708B2 (ja) 1977-07-14 1985-06-03 小野薬品工業株式会社 プロスタグランジン類似化合物
US4308595A (en) * 1979-12-19 1981-12-29 International Business Machines Corporation Array driver
US4670569A (en) 1981-04-02 1987-06-02 G. D. Searle & Co. 5-fluoro-PGI2 compounds
US4579958A (en) 1983-12-23 1986-04-01 G. D. Searle & Co. 5-fluoro-3-oxa-6,7-didehydro-PGI1 compounds
US4687864A (en) 1983-12-23 1987-08-18 G. D. Searle & Co. 5-fluoro-3-oxa-prostacyclin compounds
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
ATE78465T1 (de) 1987-10-02 1992-08-15 Ueno Seiyaku Oyo Kenkyujo Kk Kathartica.
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2030346C (en) * 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
CA2030345C (en) 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
EP0455448B1 (en) * 1990-05-01 1998-12-09 R-Tech Ueno Ltd. Treatment of pancreatic disease with 15-keto-prostaglandin E compounds
JP2515442B2 (ja) * 1990-05-01 1996-07-10 株式会社上野製薬応用研究所 膵臓疾患処置剤
JP2938579B2 (ja) 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US5958876A (en) 1996-06-19 1999-09-28 Novartis Ag Cyclosporin-containing pharmaceutical compositions
AUPO665397A0 (en) * 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
CN1160079C (zh) 1998-03-11 2004-08-04 格勒兰制药株式会社 发泡性肠溶制剂
US6471085B1 (en) 1999-10-04 2002-10-29 Anthony J. Gallo Temperature cup
DE60039727D1 (de) * 1999-10-15 2008-09-11 Sucampo Ag Neue Zusammensetzung enthaltend eine bicyclische Verbindung und ein Glycerid
DE50107923D1 (de) * 2000-07-14 2005-12-08 Henkel Kgaa Kompartiment-hohlkörper enthaltend wasch-, reinigungs- oder spülmittelportion
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition

Also Published As

Publication number Publication date
JP4684334B2 (ja) 2011-05-18
NO20030996D0 (no) 2003-03-04
US8748454B2 (en) 2014-06-10
US20050222195A1 (en) 2005-10-06
US6610732B2 (en) 2003-08-26
EP1857105A3 (en) 2008-03-05
HUP0302422A2 (hu) 2003-10-28
US20120022152A1 (en) 2012-01-26
DE60142810D1 (de) 2010-09-23
NL300757I2 (es) 2015-12-29
WO2002020007A1 (en) 2002-03-14
CN100335049C (zh) 2007-09-05
US20030216465A1 (en) 2003-11-20
NO332701B1 (no) 2012-12-10
US20140235665A1 (en) 2014-08-21
JP2009114217A (ja) 2009-05-28
KR100901102B1 (ko) 2009-06-08
KR20030029919A (ko) 2003-04-16
AU2001282615B2 (en) 2006-06-22
IL154534A0 (en) 2003-09-17
HU229319B1 (en) 2013-10-28
TWI305147B (en) 2009-01-11
ZA200301673B (en) 2003-11-26
BR0114042A (pt) 2003-07-22
HUP0302422A3 (en) 2005-02-28
ES2296786T3 (es) 2008-05-01
US20030040528A1 (en) 2003-02-27
JP2009286806A (ja) 2009-12-10
MXPA03001959A (es) 2003-06-24
US20120237598A1 (en) 2012-09-20
RU2694361C2 (ru) 2019-07-12
KR100918223B1 (ko) 2009-09-21
DK1315485T3 (da) 2008-03-03
IL154534A (en) 2010-04-29
BRPI0114042B1 (pt) 2016-11-08
US8114890B1 (en) 2012-02-14
AR030609A1 (es) 2003-08-27
DK1857105T3 (da) 2010-09-20
EP1315485B1 (en) 2007-11-21
BRPI0114042B8 (pt) 2021-05-25
CA2419741A1 (en) 2002-03-14
PT1857105E (pt) 2010-10-08
KR20080091278A (ko) 2008-10-09
RU2694361C9 (ru) 2019-12-25
EP1857105A2 (en) 2007-11-21
ATE476975T1 (de) 2010-08-15
JP2004508327A (ja) 2004-03-18
NZ524401A (en) 2004-08-27
PT1315485E (pt) 2008-01-23
CA2419741C (en) 2010-11-30
NL300757I1 (es) 2015-12-29
US8071613B2 (en) 2011-12-06
RU2694361C3 (ru) 2020-07-20
EP1315485A1 (en) 2003-06-04
DE60131547D1 (de) 2008-01-03
DE60131547T2 (de) 2008-10-23
NO20030996L (no) 2003-05-02
CZ304740B6 (cs) 2014-09-17
AU8261501A (en) 2002-03-22
ES2347697T3 (es) 2010-11-03
EP1857105B1 (en) 2010-08-11
CN1655776A (zh) 2005-08-17
US6414016B1 (en) 2002-07-02

Similar Documents

Publication Publication Date Title
ATE292460T1 (de) Zusammenstellungen die aktive stilbenoidverbindungen enthalten zur senkung des triglyceridspiegels
UY27320A1 (es) Nuevas composiciones farmacéuticas
CO5251404A1 (es) Compuestos antibioticos de azalida
JP2003520232A5 (es)
AR109354A2 (es) Una composición que comprende un compuesto bicíclico y compuesto
ID29895A (id) Batangan sabun dengan sedikit atau tanpa surfaktan sintetis
EP1857105A3 (en) Cathartic composition
PT1075259E (pt) Novos analogos gordos para o tratamento de diabetes
EA200300171A1 (ru) Циклопентаноиндолы, композиции, содержащие данные соединения, и способы лечения
HRP20050663A2 (en) Malonamide derivatives as gamma-secretase inhibitors
DE60110438D1 (de) Zusammensetzungen enthaltend stilbenoide mit einer hypoglykämischen wirkung
CO4970765A1 (es) Composiciones de bajo ph que contienen acido para el cuidado personal que exhiben picazon reducida
AR051778A2 (es) Derivados del acido dimetilaminocrotonico y procesos para supreparacion
EA200400971A1 (ru) Фторзамещенные циклоалканоиндолы, композиции, содержащие такие соединения, и способы лечения
ATE404572T1 (de) Fluorierte phosphonsäuren
DK1485359T3 (da) Natriumkanalblokkere
PT1352046E (pt) Composi??es de branqueadores ?pticos, sua produ??o e sua utiliza??o
MXPA04000634A (es) Barra de detergente mejorada y un proceso para fabricacion.
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
NO20025054L (no) Oksidasjonsprosess for fremstilling av mellomproduktet 6.alfa., 9.alfa.-difluor-11.beta., 17.alfa.-dihydroksy-16.alfa.-metyl-androst-1,4-dien-3-on 17.beta.-karboksylsyre
NO20014240D0 (no) C16-umettede FP-selektive prostaglandinanaloger
BRPI0411664A (pt) composição oral antiplaca aquosa estável
BR0114156A (pt) Forma amorfa de inibidor de ciclo de célula
GT199900193A (es) Combinaciones fungicidas que comprenden tieno [2,3-d] pirimidin-4-ona.
CO4980899A1 (es) Proceso para la sintesis de los compuestos intermediarios de cloropurina

Legal Events

Date Code Title Description
FC Refusal